#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Over the last two decades , remarkable progress has been made in understanding the etiology and pathophysiology of diseases .
1-1	0-4	Over	_	_	_	_
1-2	5-8	the	time[1]	new[1]	_	_
1-3	9-13	last	time[1]	new[1]	_	_
1-4	14-17	two	time[1]	new[1]	_	_
1-5	18-25	decades	time[1]	new[1]	_	_
1-6	26-27	,	_	_	_	_
1-7	28-38	remarkable	abstract[2]	new[2]	_	_
1-8	39-47	progress	abstract[2]	new[2]	_	_
1-9	48-51	has	_	_	_	_
1-10	52-56	been	_	_	_	_
1-11	57-61	made	_	_	_	_
1-12	62-64	in	_	_	_	_
1-13	65-78	understanding	_	_	_	_
1-14	79-82	the	abstract[3]	new[3]	_	_
1-15	83-91	etiology	abstract[3]	new[3]	_	_
1-16	92-95	and	_	_	_	_
1-17	96-111	pathophysiology	abstract[4]	new[4]	_	_
1-18	112-114	of	abstract[4]	new[4]	_	_
1-19	115-123	diseases	abstract[4]|abstract	new[4]|new	coref	3-43[25_0]
1-20	124-125	.	_	_	_	_

#Text=New discoveries emphasize the importance of the small bowel ( SB ) ‘ ecosystem ’ in the pathogenesis of acute and chronic illness alike .
2-1	126-129	New	abstract[6]	new[6]	coref	5-1[34_6]
2-2	130-141	discoveries	abstract[6]	new[6]	_	_
2-3	142-151	emphasize	_	_	_	_
2-4	152-155	the	abstract[7]	new[7]	_	_
2-5	156-166	importance	abstract[7]	new[7]	_	_
2-6	167-169	of	abstract[7]	new[7]	_	_
2-7	170-173	the	abstract[7]|object[8]	new[7]|new[8]	appos	2-11[0_8]
2-8	174-179	small	abstract[7]|object[8]	new[7]|new[8]	_	_
2-9	180-185	bowel	abstract[7]|object[8]	new[7]|new[8]	_	_
2-10	186-187	(	abstract[7]	new[7]	_	_
2-11	188-190	SB	abstract[7]|object	new[7]|giv	coref	6-11[44_0]
2-12	191-192	)	abstract[7]	new[7]	_	_
2-13	193-194	‘	abstract[7]|abstract[10]|abstract[11]	new[7]|new[10]|new[11]	_	_
2-14	195-204	ecosystem	abstract[7]|abstract[10]|abstract[11]	new[7]|new[10]|new[11]	_	_
2-15	205-206	’	abstract[7]|abstract[10]|abstract[11]	new[7]|new[10]|new[11]	_	_
2-16	207-209	in	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-17	210-213	the	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-18	214-226	pathogenesis	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-19	227-229	of	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-20	230-235	acute	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-21	236-239	and	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-22	240-247	chronic	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-23	248-255	illness	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-24	256-261	alike	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-25	262-263	.	_	_	_	_

#Text=Emerging factors , such as microbiome , stem and progenitor cells , innate intestinal immunity , and the enteric nervous system , along with mucosal and endothelial barriers , play a key role in the development of gastrointestinal ( GI ) and extra-GI diseases .
3-1	264-272	Emerging	abstract[13]	new[13]	_	_
3-2	273-280	factors	abstract[13]	new[13]	_	_
3-3	281-282	,	abstract[13]	new[13]	_	_
3-4	283-287	such	abstract[13]	new[13]	_	_
3-5	288-290	as	abstract[13]	new[13]	_	_
3-6	291-301	microbiome	abstract[13]|object	new[13]|new	_	_
3-7	302-303	,	abstract[13]	new[13]	_	_
3-8	304-308	stem	abstract[13]|plant	new[13]|new	_	_
3-9	309-312	and	abstract[13]	new[13]	_	_
3-10	313-323	progenitor	abstract[13]|object[16]	new[13]|new[16]	coref	11-9[85_16]
3-11	324-329	cells	abstract[13]|object[16]	new[13]|new[16]	_	_
3-12	330-331	,	abstract[13]	new[13]	_	_
3-13	332-338	innate	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-14	339-349	intestinal	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-15	350-358	immunity	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-16	359-360	,	abstract[13]	new[13]	_	_
3-17	361-364	and	abstract[13]	new[13]	_	_
3-18	365-368	the	abstract[13]|place[18]	new[13]|new[18]	coref	13-6[112_18]
3-19	369-376	enteric	abstract[13]|place[18]	new[13]|new[18]	_	_
3-20	377-384	nervous	abstract[13]|place[18]	new[13]|new[18]	_	_
3-21	385-391	system	abstract[13]|place[18]	new[13]|new[18]	_	_
3-22	392-393	,	_	_	_	_
3-23	394-399	along	_	_	_	_
3-24	400-404	with	_	_	_	_
3-25	405-412	mucosal	abstract|object[21]	new|new[21]	coref|coref	22-8[241_21]|22-8[241_21]
3-26	413-416	and	object[21]	new[21]	_	_
3-27	417-428	endothelial	abstract|object[21]	new|new[21]	coref	16-37
3-28	429-437	barriers	object[21]	new[21]	_	_
3-29	438-439	,	_	_	_	_
3-30	440-444	play	_	_	_	_
3-31	445-446	a	abstract[22]	new[22]	coref	6-4[42_22]
3-32	447-450	key	abstract[22]	new[22]	_	_
3-33	451-455	role	abstract[22]	new[22]	_	_
3-34	456-458	in	abstract[22]	new[22]	_	_
3-35	459-462	the	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-36	463-474	development	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-37	475-477	of	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-38	478-494	gastrointestinal	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-39	495-496	(	_	_	_	_
3-40	497-499	GI	abstract	new	coref	12-40
3-41	500-501	)	_	_	_	_
3-42	502-505	and	_	_	_	_
3-43	506-514	extra-GI	abstract[25]	giv[25]	coref	4-16[31_25]
3-44	515-523	diseases	abstract[25]	giv[25]	_	_
3-45	524-525	.	_	_	_	_

#Text=The results of other studies point also towards a link between the digestive tract and common non-communicable diseases , such as obesity and cancer .
4-1	526-529	The	abstract[26]	new[26]	coref	8-12[62_26]
4-2	530-537	results	abstract[26]	new[26]	_	_
4-3	538-540	of	abstract[26]	new[26]	_	_
4-4	541-546	other	abstract[26]	new[26]	_	_
4-5	547-554	studies	abstract[26]|event	new[26]|new	coref	6-1[41_0]
4-6	555-560	point	abstract[26]	new[26]	_	_
4-7	561-565	also	_	_	_	_
4-8	566-573	towards	_	_	_	_
4-9	574-575	a	abstract[28]	new[28]	_	_
4-10	576-580	link	abstract[28]	new[28]	_	_
4-11	581-588	between	abstract[28]	new[28]	_	_
4-12	589-592	the	abstract[28]|object[29]|abstract[30]	new[28]|new[29]|new[30]	coref|coref|coref|coref	13-1[110_29]|13-1[111_30]|13-1[110_29]|13-1[111_30]
4-13	593-602	digestive	abstract[28]|object[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
4-14	603-608	tract	abstract[28]|object[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
4-15	609-612	and	abstract[28]|abstract[30]	new[28]|new[30]	_	_
4-16	613-619	common	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	coref	19-22[172_31]
4-17	620-636	non-communicable	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-18	637-645	diseases	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-19	646-647	,	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-20	648-652	such	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-21	653-655	as	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-22	656-663	obesity	abstract[28]|abstract[30]|abstract[31]|abstract	new[28]|new[30]|giv[31]|new	coref	7-20
4-23	664-667	and	abstract[28]|abstract[30]|abstract[31]	new[28]|new[30]|giv[31]	_	_
4-24	668-674	cancer	abstract[28]|abstract[30]|abstract[31]|abstract	new[28]|new[30]|giv[31]|new	_	_
4-25	675-676	.	_	_	_	_

#Text=These discoveries unravel novel dimensions of uncertainty in the area of clinical decision-making motivating researchers to search for novel diagnostic and therapeutic solutions .
5-1	677-682	These	abstract[34]	giv[34]	_	_
5-2	683-694	discoveries	abstract[34]	giv[34]	_	_
5-3	695-702	unravel	_	_	_	_
5-4	703-708	novel	abstract[35]	new[35]	_	_
5-5	709-719	dimensions	abstract[35]	new[35]	_	_
5-6	720-722	of	abstract[35]	new[35]	_	_
5-7	723-734	uncertainty	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-8	735-737	in	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-9	738-741	the	abstract[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	_	_
5-10	742-746	area	abstract[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	_	_
5-11	747-749	of	abstract[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	_	_
5-12	750-758	clinical	abstract[35]|abstract[36]|abstract[37]|abstract[38]	new[35]|new[36]|new[37]|new[38]	_	_
5-13	759-774	decision-making	abstract[35]|abstract[36]|abstract[37]|abstract[38]	new[35]|new[36]|new[37]|new[38]	_	_
5-14	775-785	motivating	_	_	_	_
5-15	786-797	researchers	person	new	_	_
5-16	798-800	to	_	_	_	_
5-17	801-807	search	_	_	_	_
5-18	808-811	for	_	_	_	_
5-19	812-817	novel	_	_	_	_
5-20	818-828	diagnostic	abstract[40]	new[40]	_	_
5-21	829-832	and	abstract[40]	new[40]	_	_
5-22	833-844	therapeutic	abstract[40]	new[40]	_	_
5-23	845-854	solutions	abstract[40]	new[40]	_	_
5-24	855-856	.	_	_	_	_

#Text=Recent studies unravel the role of the poorly-understood complexity of the SB .
6-1	857-863	Recent	event[41]	giv[41]	_	_
6-2	864-871	studies	event[41]	giv[41]	_	_
6-3	872-879	unravel	_	_	_	_
6-4	880-883	the	abstract[42]	giv[42]	coref	7-7[48_42]
6-5	884-888	role	abstract[42]	giv[42]	_	_
6-6	889-891	of	abstract[42]	giv[42]	_	_
6-7	892-895	the	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-8	896-913	poorly-understood	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-9	914-924	complexity	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-10	925-927	of	abstract[42]|abstract[43]	giv[42]|new[43]	_	_
6-11	928-931	the	abstract[42]|abstract[43]|object[44]	giv[42]|new[43]|giv[44]	ana	7-3[0_44]
6-12	932-934	SB	abstract[42]|abstract[43]|object[44]	giv[42]|new[43]|giv[44]	_	_
6-13	935-936	.	_	_	_	_

#Text=Insights into its critical physiologic and pathophysiologic role in metabolic homeostasis and its potential role as a driver of obesity , insulin resistance , and subsequent type 2 diabetes mellitus ( T2DM ) have been revealed .
7-1	937-945	Insights	abstract[45]	new[45]	_	_
7-2	946-950	into	abstract[45]	new[45]	_	_
7-3	951-954	its	abstract[45]|object|abstract[47]	new[45]|giv|new[47]	ana|ana	7-13|7-13
7-4	955-963	critical	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-5	964-975	physiologic	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-6	976-979	and	abstract[45]	new[45]	_	_
7-7	980-996	pathophysiologic	abstract[45]|abstract[48]	new[45]|giv[48]	coref	19-15[170_48]
7-8	997-1001	role	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-9	1002-1004	in	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-10	1005-1014	metabolic	abstract[45]|abstract[48]|person|abstract[50]	new[45]|giv[48]|new|new[50]	coref|coref|coref|coref	8-18|9-24[73_50]|8-18|9-24[73_50]
7-11	1015-1026	homeostasis	abstract[45]|abstract[48]|abstract[50]	new[45]|giv[48]|new[50]	_	_
7-12	1027-1030	and	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-13	1031-1034	its	abstract[45]|abstract[48]|object	new[45]|giv[48]|giv	coref	19-40
7-14	1035-1044	potential	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-15	1045-1049	role	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-16	1050-1052	as	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-17	1053-1054	a	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-18	1055-1061	driver	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-19	1062-1064	of	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-20	1065-1072	obesity	abstract[45]|abstract[48]|abstract	new[45]|giv[48]|giv	coref	19-37[176_0]
7-21	1073-1074	,	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-22	1075-1082	insulin	abstract[45]|abstract[48]|event|abstract[54]	new[45]|giv[48]|new|new[54]	coref|coref|coref|coref	10-24|10-24[80_54]|10-24|10-24[80_54]
7-23	1083-1093	resistance	abstract[45]|abstract[48]|abstract[54]	new[45]|giv[48]|new[54]	_	_
7-24	1094-1095	,	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-25	1096-1099	and	abstract[45]|abstract[48]	new[45]|giv[48]	_	_
7-26	1100-1110	subsequent	abstract[45]|abstract[48]|abstract[55]	new[45]|giv[48]|new[55]	appos	7-28[57_55]
7-27	1111-1115	type	abstract[45]|abstract[48]|abstract[55]	new[45]|giv[48]|new[55]	_	_
7-28	1116-1117	2	abstract[57]	giv[57]	appos	7-32[0_57]
7-29	1118-1126	diabetes	abstract|abstract[57]	new|giv[57]	coref	25-16
7-30	1127-1135	mellitus	abstract[57]	giv[57]	_	_
7-31	1136-1137	(	_	_	_	_
7-32	1138-1142	T2DM	abstract	giv	coref	10-29
7-33	1143-1144	)	_	_	_	_
7-34	1145-1149	have	_	_	_	_
7-35	1150-1154	been	_	_	_	_
7-36	1155-1163	revealed	_	_	_	_
7-37	1164-1165	.	_	_	_	_

#Text=For example , bypassing the proximal small intestine by means of bariatric surgery results in a significant metabolic benefit to an individual undergoing such a procedure .
8-1	1166-1169	For	_	_	_	_
8-2	1170-1177	example	_	_	_	_
8-3	1178-1179	,	_	_	_	_
8-4	1180-1189	bypassing	_	_	_	_
8-5	1190-1193	the	object[59]	new[59]	coref	12-12[100_59]
8-6	1194-1202	proximal	object[59]	new[59]	_	_
8-7	1203-1208	small	object[59]	new[59]	_	_
8-8	1209-1218	intestine	object[59]	new[59]	_	_
8-9	1219-1221	by	_	_	_	_
8-10	1222-1227	means	_	_	_	_
8-11	1228-1230	of	_	_	_	_
8-12	1231-1240	bariatric	abstract|abstract[62]	new|giv[62]	_	_
8-13	1241-1248	surgery	event|abstract[62]	new|giv[62]	_	_
8-14	1249-1256	results	abstract[62]	giv[62]	_	_
8-15	1257-1259	in	_	_	_	_
8-16	1260-1261	a	abstract[64]	new[64]	_	_
8-17	1262-1273	significant	abstract[64]	new[64]	_	_
8-18	1274-1283	metabolic	person|abstract[64]	giv|new[64]	coref	12-37
8-19	1284-1291	benefit	abstract[64]	new[64]	_	_
8-20	1292-1294	to	abstract[64]	new[64]	_	_
8-21	1295-1297	an	abstract[64]	new[64]	_	_
8-22	1298-1308	individual	abstract[64]	new[64]	_	_
8-23	1309-1319	undergoing	_	_	_	_
8-24	1320-1324	such	event[65]	new[65]	_	_
8-25	1325-1326	a	event[65]	new[65]	_	_
8-26	1327-1336	procedure	event[65]	new[65]	_	_
8-27	1337-1338	.	_	_	_	_

#Text=Moreover , endoscopic procedures aimed at placing devices separating luminal contents from the duodenal mucosa result in modest weight loss and improvement in glucose homeostasis .
9-1	1339-1347	Moreover	abstract[66]	new[66]	_	_
9-2	1348-1349	,	abstract[66]	new[66]	_	_
9-3	1350-1360	endoscopic	abstract[66]	new[66]	_	_
9-4	1361-1371	procedures	abstract[66]	new[66]	_	_
9-5	1372-1377	aimed	_	_	_	_
9-6	1378-1380	at	_	_	_	_
9-7	1381-1388	placing	_	_	_	_
9-8	1389-1396	devices	object	new	_	_
9-9	1397-1407	separating	_	_	_	_
9-10	1408-1415	luminal	object[68]	new[68]	_	_
9-11	1416-1424	contents	object[68]	new[68]	_	_
9-12	1425-1429	from	_	_	_	_
9-13	1430-1433	the	_	_	_	_
9-14	1434-1442	duodenal	_	_	_	_
9-15	1443-1449	mucosa	object	new	coref	10-8[75_0]
9-16	1450-1456	result	_	_	_	_
9-17	1457-1459	in	_	_	_	_
9-18	1460-1466	modest	abstract[70]	new[70]	_	_
9-19	1467-1473	weight	abstract[70]	new[70]	_	_
9-20	1474-1478	loss	abstract[70]	new[70]	_	_
9-21	1479-1482	and	_	_	_	_
9-22	1483-1494	improvement	abstract[71]	new[71]	coref	10-20[77_71]
9-23	1495-1497	in	abstract[71]	new[71]	_	_
9-24	1498-1505	glucose	abstract[71]|substance|abstract[73]	new[71]|new|giv[73]	_	_
9-25	1506-1517	homeostasis	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-26	1518-1519	.	_	_	_	_

#Text=Another endoscopic treatment which aims at resurfacing duodenal mucosa ( DMR , duodenal mucosal resurfacing ) , leads to improvement in glycemia and insulin resistance in patients with T2DM .
10-1	1520-1527	Another	abstract[74]	new[74]	_	_
10-2	1528-1538	endoscopic	abstract[74]	new[74]	_	_
10-3	1539-1548	treatment	abstract[74]	new[74]	_	_
10-4	1549-1554	which	_	_	_	_
10-5	1555-1559	aims	_	_	_	_
10-6	1560-1562	at	_	_	_	_
10-7	1563-1574	resurfacing	_	_	_	_
10-8	1575-1583	duodenal	object[75]	giv[75]	appos	10-11[0_75]
10-9	1584-1590	mucosa	object[75]	giv[75]	_	_
10-10	1591-1592	(	_	_	_	_
10-11	1593-1596	DMR	object	giv	_	_
10-12	1597-1598	,	_	_	_	_
10-13	1599-1607	duodenal	_	_	_	_
10-14	1608-1615	mucosal	_	_	_	_
10-15	1616-1627	resurfacing	_	_	_	_
10-16	1628-1629	)	_	_	_	_
10-17	1630-1631	,	_	_	_	_
10-18	1632-1637	leads	_	_	_	_
10-19	1638-1640	to	_	_	_	_
10-20	1641-1652	improvement	abstract[77]	giv[77]	_	_
10-21	1653-1655	in	abstract[77]	giv[77]	_	_
10-22	1656-1664	glycemia	abstract[77]|abstract	giv[77]|new	_	_
10-23	1665-1668	and	abstract[77]	giv[77]	_	_
10-24	1669-1676	insulin	abstract[77]|event|abstract[80]	giv[77]|giv|giv[80]	_	_
10-25	1677-1687	resistance	abstract[77]|abstract[80]	giv[77]|giv[80]	_	_
10-26	1688-1690	in	abstract[77]|abstract[80]	giv[77]|giv[80]	_	_
10-27	1691-1699	patients	abstract[77]|abstract[80]|person[81]	giv[77]|giv[80]|new[81]	coref	21-6[227_81]
10-28	1700-1704	with	abstract[77]|abstract[80]|person[81]	giv[77]|giv[80]|new[81]	_	_
10-29	1705-1709	T2DM	abstract[77]|abstract[80]|person[81]|abstract	giv[77]|giv[80]|new[81]|giv	ana	11-1
10-30	1710-1711	.	_	_	_	_

#Text=It is not surprising when we recall that SB endocrine cells secrete glycemia-regulating incretin hormones ( e. g. , glucagon-like peptide , GLP-1 ) , and this process is dependent on food content in the intestinal lumen .
11-1	1712-1714	It	abstract	giv	coref	25-16[273_0]
11-2	1715-1717	is	_	_	_	_
11-3	1718-1721	not	_	_	_	_
11-4	1722-1732	surprising	_	_	_	_
11-5	1733-1737	when	_	_	_	_
11-6	1738-1740	we	person	acc	ana	30-11
11-7	1741-1747	recall	_	_	_	_
11-8	1748-1752	that	_	_	_	_
11-9	1753-1755	SB	object[85]	giv[85]	coref	16-18[142_85]
11-10	1756-1765	endocrine	object[85]	giv[85]	_	_
11-11	1766-1771	cells	object[85]	giv[85]	_	_
11-12	1772-1779	secrete	_	_	_	_
11-13	1780-1799	glycemia-regulating	substance[87]	new[87]	appos	11-20[89_87]
11-14	1800-1808	incretin	abstract|substance[87]	new|new[87]	_	_
11-15	1809-1817	hormones	substance[87]	new[87]	_	_
11-16	1818-1819	(	_	_	_	_
11-17	1820-1822	e.	_	_	_	_
11-18	1823-1825	g.	_	_	_	_
11-19	1826-1827	,	_	_	_	_
11-20	1828-1841	glucagon-like	abstract|substance[89]	new|giv[89]	coref|coref	15-27[130_89]|15-27[130_89]
11-21	1842-1849	peptide	substance[89]	giv[89]	_	_
11-22	1850-1851	,	_	_	_	_
11-23	1852-1857	GLP-1	abstract	new	_	_
11-24	1858-1859	)	_	_	_	_
11-25	1860-1861	,	_	_	_	_
11-26	1862-1865	and	_	_	_	_
11-27	1866-1870	this	abstract[91]	new[91]	coref	19-66[188_91]
11-28	1871-1878	process	abstract[91]	new[91]	_	_
11-29	1879-1881	is	_	_	_	_
11-30	1882-1891	dependent	_	_	_	_
11-31	1892-1894	on	_	_	_	_
11-32	1895-1899	food	substance|abstract[93]	new|new[93]	_	_
11-33	1900-1907	content	abstract[93]	new[93]	_	_
11-34	1908-1910	in	abstract[93]	new[93]	_	_
11-35	1911-1914	the	abstract[93]|place[95]	new[93]|new[95]	_	_
11-36	1915-1925	intestinal	abstract[93]|person|place[95]	new[93]|new|new[95]	coref	19-49
11-37	1926-1931	lumen	abstract[93]|place[95]	new[93]|new[95]	_	_
11-38	1932-1933	.	_	_	_	_

#Text=Moreover , bile acids with various targets in the liver and small intestine ( e. g. , farnesoid receptor , FXR ) together with a plethora of other small signaling molecules act in concert in regulating metabolic and digestive GI function .
12-1	1934-1942	Moreover	_	_	_	_
12-2	1943-1944	,	_	_	_	_
12-3	1945-1949	bile	object|substance[97]	new|new[97]	_	_
12-4	1950-1955	acids	substance[97]	new[97]	_	_
12-5	1956-1960	with	substance[97]	new[97]	_	_
12-6	1961-1968	various	substance[97]|abstract[98]	new[97]|new[98]	_	_
12-7	1969-1976	targets	substance[97]|abstract[98]	new[97]|new[98]	_	_
12-8	1977-1979	in	substance[97]|abstract[98]	new[97]|new[98]	_	_
12-9	1980-1983	the	substance[97]|abstract[98]|object[99]	new[97]|new[98]|new[99]	coref	21-27[0_99]
12-10	1984-1989	liver	substance[97]|abstract[98]|object[99]	new[97]|new[98]|new[99]	_	_
12-11	1990-1993	and	substance[97]|abstract[98]	new[97]|new[98]	_	_
12-12	1994-1999	small	substance[97]|abstract[98]|object[100]	new[97]|new[98]|giv[100]	coref	19-133[209_100]
12-13	2000-2009	intestine	substance[97]|abstract[98]|object[100]	new[97]|new[98]|giv[100]	_	_
12-14	2010-2011	(	_	_	_	_
12-15	2012-2014	e.	_	_	_	_
12-16	2015-2017	g.	_	_	_	_
12-17	2018-2019	,	_	_	_	_
12-18	2020-2029	farnesoid	object|substance[102]	new|new[102]	_	_
12-19	2030-2038	receptor	substance[102]	new[102]	_	_
12-20	2039-2040	,	_	_	_	_
12-21	2041-2044	FXR	abstract	new	_	_
12-22	2045-2046	)	_	_	_	_
12-23	2047-2055	together	abstract[104]	new[104]	_	_
12-24	2056-2060	with	abstract[104]	new[104]	_	_
12-25	2061-2062	a	abstract[104]	new[104]	_	_
12-26	2063-2071	plethora	abstract[104]	new[104]	_	_
12-27	2072-2074	of	abstract[104]	new[104]	_	_
12-28	2075-2080	other	abstract[104]|substance[105]	new[104]|new[105]	_	_
12-29	2081-2086	small	abstract[104]|substance[105]	new[104]|new[105]	_	_
12-30	2087-2096	signaling	abstract[104]|substance[105]	new[104]|new[105]	_	_
12-31	2097-2106	molecules	abstract[104]|substance[105]	new[104]|new[105]	_	_
12-32	2107-2110	act	_	_	_	_
12-33	2111-2113	in	_	_	_	_
12-34	2114-2121	concert	event	new	_	_
12-35	2122-2124	in	_	_	_	_
12-36	2125-2135	regulating	_	_	_	_
12-37	2136-2145	metabolic	person	giv	coref	25-11
12-38	2146-2149	and	_	_	_	_
12-39	2150-2159	digestive	abstract[109]	new[109]	coref	17-7[156_109]
12-40	2160-2162	GI	organization|abstract[109]	giv|new[109]	coref	30-24[305_0]
12-41	2163-2171	function	abstract[109]	new[109]	_	_
12-42	2172-2173	.	_	_	_	_

#Text=The human digestive tract and enteric nervous system ( ENS ) communicate with the central nervous system ( CNS ) through the gut-brain axis ( GBA ) .
13-1	2174-2177	The	object[110]|abstract[111]	giv[110]|giv[111]	_	_
13-2	2178-2183	human	object[110]|abstract[111]	giv[110]|giv[111]	_	_
13-3	2184-2193	digestive	object[110]|abstract[111]	giv[110]|giv[111]	_	_
13-4	2194-2199	tract	object[110]|abstract[111]	giv[110]|giv[111]	_	_
13-5	2200-2203	and	abstract[111]	giv[111]	_	_
13-6	2204-2211	enteric	abstract[111]|place[112]	giv[111]|giv[112]	appos	13-10[0_112]
13-7	2212-2219	nervous	abstract[111]|place[112]	giv[111]|giv[112]	_	_
13-8	2220-2226	system	abstract[111]|place[112]	giv[111]|giv[112]	_	_
13-9	2227-2228	(	_	_	_	_
13-10	2229-2232	ENS	place	giv	coref	13-14[114_0]
13-11	2233-2234	)	_	_	_	_
13-12	2235-2246	communicate	_	_	_	_
13-13	2247-2251	with	_	_	_	_
13-14	2252-2255	the	place[114]	giv[114]	appos	13-19[0_114]
13-15	2256-2263	central	place[114]	giv[114]	_	_
13-16	2264-2271	nervous	place[114]	giv[114]	_	_
13-17	2272-2278	system	place[114]	giv[114]	_	_
13-18	2279-2280	(	_	_	_	_
13-19	2281-2284	CNS	place	giv	coref	14-18[122_0]
13-20	2285-2286	)	_	_	_	_
13-21	2287-2294	through	_	_	_	_
13-22	2295-2298	the	abstract[116]	new[116]	coref	15-7[125_116]
13-23	2299-2308	gut-brain	abstract[116]	new[116]	_	_
13-24	2309-2313	axis	abstract[116]	new[116]	_	_
13-25	2314-2315	(	_	_	_	_
13-26	2316-2319	GBA	object	new	coref	16-9
13-27	2320-2321	)	_	_	_	_
13-28	2322-2323	.	_	_	_	_

#Text=This bidirectional communication involves diverse neural networks through the X cranial vagal nerve — dorsal roots of the sympathetic/ parasympathetic nervous system .
14-1	2324-2328	This	abstract[118]	new[118]	coref	18-1[161_118]
14-2	2329-2342	bidirectional	abstract[118]	new[118]	_	_
14-3	2343-2356	communication	abstract[118]	new[118]	_	_
14-4	2357-2365	involves	_	_	_	_
14-5	2366-2373	diverse	place[119]	new[119]	_	_
14-6	2374-2380	neural	place[119]	new[119]	_	_
14-7	2381-2389	networks	place[119]	new[119]	_	_
14-8	2390-2397	through	place[119]	new[119]	_	_
14-9	2398-2401	the	place[119]|object[120]	new[119]|new[120]	_	_
14-10	2402-2403	X	place[119]|object[120]	new[119]|new[120]	_	_
14-11	2404-2411	cranial	place[119]|object[120]	new[119]|new[120]	_	_
14-12	2412-2417	vagal	place[119]|object[120]	new[119]|new[120]	_	_
14-13	2418-2423	nerve	place[119]|object[120]	new[119]|new[120]	_	_
14-14	2424-2425	—	_	_	_	_
14-15	2426-2432	dorsal	abstract[121]	new[121]	_	_
14-16	2433-2438	roots	abstract[121]	new[121]	_	_
14-17	2439-2441	of	abstract[121]	new[121]	_	_
14-18	2442-2445	the	abstract[121]|place[122]	new[121]|giv[122]	coref	19-83[196_122]
14-19	2446-2458	sympathetic/	abstract[121]|place[122]	new[121]|giv[122]	_	_
14-20	2459-2474	parasympathetic	abstract[121]|place[122]	new[121]|giv[122]	_	_
14-21	2475-2482	nervous	abstract[121]|place[122]	new[121]|giv[122]	_	_
14-22	2483-2489	system	abstract[121]|place[122]	new[121]|giv[122]	_	_
14-23	2490-2491	.	_	_	_	_

#Text=Important roles in the regulation of the gut-brain axis are played by : ( i ) the hypothalamus-pituitary-adrenal axis ( HPA ) , ( ii ) the stress hormones ( cortisol ) , ( iii ) the short-chain fatty acids ( SCFAs ) , and ( iv ) the gut microbiota .
15-1	2492-2501	Important	abstract[123]	new[123]	_	_
15-2	2502-2507	roles	abstract[123]	new[123]	_	_
15-3	2508-2510	in	abstract[123]	new[123]	_	_
15-4	2511-2514	the	abstract[123]|abstract[124]	new[123]|new[124]	_	_
15-5	2515-2525	regulation	abstract[123]|abstract[124]	new[123]|new[124]	_	_
15-6	2526-2528	of	abstract[123]|abstract[124]	new[123]|new[124]	_	_
15-7	2529-2532	the	abstract[123]|abstract[124]|abstract[125]	new[123]|new[124]|giv[125]	coref	15-17[126_125]
15-8	2533-2542	gut-brain	abstract[123]|abstract[124]|abstract[125]	new[123]|new[124]|giv[125]	_	_
15-9	2543-2547	axis	abstract[123]|abstract[124]|abstract[125]	new[123]|new[124]|giv[125]	_	_
15-10	2548-2551	are	_	_	_	_
15-11	2552-2558	played	_	_	_	_
15-12	2559-2561	by	_	_	_	_
15-13	2562-2563	:	_	_	_	_
15-14	2564-2565	(	_	_	_	_
15-15	2566-2567	i	_	_	_	_
15-16	2568-2569	)	_	_	_	_
15-17	2570-2573	the	abstract[126]	giv[126]	appos	15-21[0_126]
15-18	2574-2604	hypothalamus-pituitary-adrenal	abstract[126]	giv[126]	_	_
15-19	2605-2609	axis	abstract[126]	giv[126]	_	_
15-20	2610-2611	(	_	_	_	_
15-21	2612-2615	HPA	abstract	giv	appos	15-25
15-22	2616-2617	)	_	_	_	_
15-23	2618-2619	,	_	_	_	_
15-24	2620-2621	(	_	_	_	_
15-25	2622-2624	ii	abstract	giv	_	_
15-26	2625-2626	)	_	_	_	_
15-27	2627-2630	the	abstract[130]	giv[130]	appos	15-31[0_130]
15-28	2631-2637	stress	abstract|abstract[130]	new|giv[130]	_	_
15-29	2638-2646	hormones	abstract[130]	giv[130]	_	_
15-30	2647-2648	(	_	_	_	_
15-31	2649-2657	cortisol	abstract	giv	appos	15-35
15-32	2658-2659	)	_	_	_	_
15-33	2660-2661	,	_	_	_	_
15-34	2662-2663	(	_	_	_	_
15-35	2664-2667	iii	substance	giv	appos	15-37[134_0]
15-36	2668-2669	)	_	_	_	_
15-37	2670-2673	the	person[134]	giv[134]	appos	15-42[0_134]
15-38	2674-2685	short-chain	person[134]	giv[134]	_	_
15-39	2686-2691	fatty	abstract|person[134]	new|giv[134]	_	_
15-40	2692-2697	acids	person[134]	giv[134]	_	_
15-41	2698-2699	(	_	_	_	_
15-42	2700-2705	SCFAs	abstract	giv	appos	15-47
15-43	2706-2707	)	_	_	_	_
15-44	2708-2709	,	_	_	_	_
15-45	2710-2713	and	_	_	_	_
15-46	2714-2715	(	_	_	_	_
15-47	2716-2718	iv	person	giv	coref	16-35
15-48	2719-2720	)	_	_	_	_
15-49	2721-2724	the	object[138]	new[138]	_	_
15-50	2725-2728	gut	abstract|object[138]	new|new[138]	coref	20-21
15-51	2729-2739	microbiota	object[138]	new[138]	_	_
15-52	2740-2741	.	_	_	_	_

#Text=The intestinal barrier , another important part of GBA , is composed of : ( i ) goblet cells derived mucus , ( ii ) microbiota , ( iii ) epithelial cells , ( iv ) endothelial cells , ( v ) lymphatic vessels , and v ) enterocytes ’ tight cellular junctions .
16-1	2742-2745	The	object[139]	new[139]	coref	17-9[158_139]
16-2	2746-2756	intestinal	object[139]	new[139]	_	_
16-3	2757-2764	barrier	object[139]	new[139]	_	_
16-4	2765-2766	,	_	_	_	_
16-5	2767-2774	another	_	_	_	_
16-6	2775-2784	important	_	_	_	_
16-7	2785-2789	part	_	_	_	_
16-8	2790-2792	of	_	_	_	_
16-9	2793-2796	GBA	object	giv	_	_
16-10	2797-2798	,	_	_	_	_
16-11	2799-2801	is	_	_	_	_
16-12	2802-2810	composed	_	_	_	_
16-13	2811-2813	of	_	_	_	_
16-14	2814-2815	:	_	_	_	_
16-15	2816-2817	(	_	_	_	_
16-16	2818-2819	i	_	_	_	_
16-17	2820-2821	)	_	_	_	_
16-18	2822-2828	goblet	object|object[142]	new|giv[142]	_	_
16-19	2829-2834	cells	object[142]	giv[142]	_	_
16-20	2835-2842	derived	_	_	_	_
16-21	2843-2848	mucus	abstract	new	appos	16-24
16-22	2849-2850	,	_	_	_	_
16-23	2851-2852	(	_	_	_	_
16-24	2853-2855	ii	place	giv	appos	16-26
16-25	2856-2857	)	_	_	_	_
16-26	2858-2868	microbiota	abstract	giv	appos	16-29
16-27	2869-2870	,	_	_	_	_
16-28	2871-2872	(	_	_	_	_
16-29	2873-2876	iii	abstract	giv	appos	16-31[147_0]
16-30	2877-2878	)	_	_	_	_
16-31	2879-2889	epithelial	object[147]	giv[147]	appos	16-37[150_147]
16-32	2890-2895	cells	object[147]	giv[147]	_	_
16-33	2896-2897	,	_	_	_	_
16-34	2898-2899	(	_	_	_	_
16-35	2900-2902	iv	person	giv	_	_
16-36	2903-2904	)	_	_	_	_
16-37	2905-2916	endothelial	object|object[150]	giv|giv[150]	appos|appos	16-47[0_150]|16-47[0_150]
16-38	2917-2922	cells	object[150]	giv[150]	_	_
16-39	2923-2924	,	object[150]	giv[150]	_	_
16-40	2925-2926	(	object[150]	giv[150]	_	_
16-41	2927-2928	v	object[150]|abstract	giv[150]|new	_	_
16-42	2929-2930	)	object[150]	giv[150]	_	_
16-43	2931-2940	lymphatic	object[150]	giv[150]	_	_
16-44	2941-2948	vessels	object[150]	giv[150]	_	_
16-45	2949-2950	,	_	_	_	_
16-46	2951-2954	and	_	_	_	_
16-47	2955-2956	v	abstract	giv	appos	16-49[154_0]
16-48	2957-2958	)	_	_	_	_
16-49	2959-2970	enterocytes	abstract[153]|place[154]	new[153]|giv[154]	_	_
16-50	2971-2972	’	abstract[153]|place[154]	new[153]|giv[154]	_	_
16-51	2973-2978	tight	place[154]	giv[154]	_	_
16-52	2979-2987	cellular	place[154]	giv[154]	_	_
16-53	2988-2997	junctions	place[154]	giv[154]	_	_
16-54	2998-2999	.	_	_	_	_

#Text=Of interest , the structure and function of the intestinal barrier resemble that of the blood-brain barrier ( BBB ) .
17-1	3000-3002	Of	_	_	_	_
17-2	3003-3011	interest	_	_	_	_
17-3	3012-3013	,	_	_	_	_
17-4	3014-3017	the	abstract[155]	new[155]	_	_
17-5	3018-3027	structure	abstract[155]	new[155]	_	_
17-6	3028-3031	and	_	_	_	_
17-7	3032-3040	function	abstract[156]	giv[156]	coref	19-49[182_156]
17-8	3041-3043	of	abstract[156]	giv[156]	_	_
17-9	3044-3047	the	abstract[156]|object[158]	giv[156]|giv[158]	coref	17-15[159_158]
17-10	3048-3058	intestinal	abstract[156]|abstract|object[158]	giv[156]|new|giv[158]	coref	19-12
17-11	3059-3066	barrier	abstract[156]|object[158]	giv[156]|giv[158]	_	_
17-12	3067-3075	resemble	_	_	_	_
17-13	3076-3080	that	_	_	_	_
17-14	3081-3083	of	_	_	_	_
17-15	3084-3087	the	object[159]	giv[159]	coref	19-11[169_159]
17-16	3088-3099	blood-brain	object[159]	giv[159]	_	_
17-17	3100-3107	barrier	object[159]	giv[159]	_	_
17-18	3108-3109	(	_	_	_	_
17-19	3110-3113	BBB	place	new	_	_
17-20	3114-3115	)	_	_	_	_
17-21	3116-3117	.	_	_	_	_

#Text=The gut-brain communication is mediated via blood , portal/hepatic circulation , and the bone marrow .
18-1	3118-3121	The	abstract[161]	giv[161]	_	_
18-2	3122-3131	gut-brain	abstract[161]	giv[161]	_	_
18-3	3132-3145	communication	abstract[161]	giv[161]	_	_
18-4	3146-3148	is	_	_	_	_
18-5	3149-3157	mediated	_	_	_	_
18-6	3158-3161	via	_	_	_	_
18-7	3162-3167	blood	substance	new	_	_
18-8	3168-3169	,	_	_	_	_
18-9	3170-3184	portal/hepatic	abstract[163]	new[163]	ana	19-3[0_163]
18-10	3185-3196	circulation	abstract[163]	new[163]	_	_
18-11	3197-3198	,	_	_	_	_
18-12	3199-3202	and	_	_	_	_
18-13	3203-3206	the	object[165]	new[165]	_	_
18-14	3207-3211	bone	object|object[165]	new|new[165]	_	_
18-15	3212-3218	marrow	object[165]	new[165]	_	_
18-16	3219-3220	.	_	_	_	_

#Text=Recently , it has been described that the alterations of the intestinal barrier play a crucial role in the pathology of several human inflammatory and autoimmune diseases . Mohanan et al. documented the crucial role of the C1orf106 inflammatory bowel disease ( IBD ) susceptibility gene in stabilizing intestinal barrier function and intestinal inflammation . Manfredo Vieira et al. evidenced the role of pathobionts in the process of intestinal barrier alterations , which were followed by their translocation to lymph nodes and the hepatic portal system , triggering systemic lupus erythematosus ( SLE ) . Thaiss et al. reported that hyperglycemia leads to disruption of the intestinal barrier followed by intestinal inflammation and systemic infection . Spadoni et al. recently documented that the presence of the gut-vascular barrier ( GVB ) in the small intestine controls the dissemination of bacteria into the bloodstream .
19-1	3221-3229	Recently	_	_	_	_
19-2	3230-3231	,	_	_	_	_
19-3	3232-3234	it	abstract	giv	_	_
19-4	3235-3238	has	_	_	_	_
19-5	3239-3243	been	_	_	_	_
19-6	3244-3253	described	_	_	_	_
19-7	3254-3258	that	_	_	_	_
19-8	3259-3262	the	abstract[167]	new[167]	coref	19-69[190_167]
19-9	3263-3274	alterations	abstract[167]	new[167]	_	_
19-10	3275-3277	of	abstract[167]	new[167]	_	_
19-11	3278-3281	the	abstract[167]|object[169]	new[167]|giv[169]	coref	19-50[0_169]
19-12	3282-3292	intestinal	abstract[167]|abstract|object[169]	new[167]|giv|giv[169]	_	_
19-13	3293-3300	barrier	abstract[167]|object[169]	new[167]|giv[169]	_	_
19-14	3301-3305	play	_	_	_	_
19-15	3306-3307	a	abstract[170]	giv[170]	_	_
19-16	3308-3315	crucial	abstract[170]	giv[170]	_	_
19-17	3316-3320	role	abstract[170]	giv[170]	_	_
19-18	3321-3323	in	abstract[170]	giv[170]	_	_
19-19	3324-3327	the	abstract[170]|abstract[171]	giv[170]|new[171]	_	_
19-20	3328-3337	pathology	abstract[170]|abstract[171]	giv[170]|new[171]	_	_
19-21	3338-3340	of	abstract[170]|abstract[171]	giv[170]|new[171]	_	_
19-22	3341-3348	several	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	coref	30-27[306_172]
19-23	3349-3354	human	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	_	_
19-24	3355-3367	inflammatory	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	_	_
19-25	3368-3371	and	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	_	_
19-26	3372-3382	autoimmune	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	_	_
19-27	3383-3391	diseases	abstract[170]|abstract[171]|abstract[172]	giv[170]|new[171]|giv[172]	_	_
19-28	3392-3393	.	_	_	_	_
19-29	3394-3401	Mohanan	person	new	_	_
19-30	3402-3404	et	_	_	_	_
19-31	3405-3408	al.	_	_	_	_
19-32	3409-3419	documented	_	_	_	_
19-33	3420-3423	the	abstract[174]	new[174]	_	_
19-34	3424-3431	crucial	abstract[174]	new[174]	_	_
19-35	3432-3436	role	abstract[174]	new[174]	_	_
19-36	3437-3439	of	abstract[174]	new[174]	_	_
19-37	3440-3443	the	abstract[174]|abstract[176]	new[174]|giv[176]	appos	19-43[0_176]
19-38	3444-3452	C1orf106	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
19-39	3453-3465	inflammatory	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
19-40	3466-3471	bowel	abstract[174]|object|abstract[176]	new[174]|giv|giv[176]	coref	20-30[225_0]
19-41	3472-3479	disease	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
19-42	3480-3481	(	_	_	_	_
19-43	3482-3485	IBD	abstract	giv	coref	21-8[229_0]
19-44	3486-3487	)	_	_	_	_
19-45	3488-3502	susceptibility	abstract|abstract[179]	new|new[179]	coref|coref	20-10[0_179]|20-10[0_179]
19-46	3503-3507	gene	abstract[179]	new[179]	_	_
19-47	3508-3510	in	_	_	_	_
19-48	3511-3522	stabilizing	_	_	_	_
19-49	3523-3533	intestinal	person|abstract[182]	giv|giv[182]	coref|coref	19-53|19-53
19-50	3534-3541	barrier	object|abstract[182]	giv|giv[182]	coref	19-70
19-51	3542-3550	function	abstract[182]	giv[182]	_	_
19-52	3551-3554	and	_	_	_	_
19-53	3555-3565	intestinal	object|abstract[184]	giv|new[184]	coref|coref	19-111[204_184]|19-111[204_184]
19-54	3566-3578	inflammation	abstract[184]	new[184]	_	_
19-55	3579-3580	.	_	_	_	_
19-56	3581-3589	Manfredo	person[185]	new[185]	_	_
19-57	3590-3596	Vieira	person[185]	new[185]	_	_
19-58	3597-3599	et	_	_	_	_
19-59	3600-3603	al.	_	_	_	_
19-60	3604-3613	evidenced	_	_	_	_
19-61	3614-3617	the	abstract[186]	new[186]	_	_
19-62	3618-3622	role	abstract[186]	new[186]	_	_
19-63	3623-3625	of	abstract[186]	new[186]	_	_
19-64	3626-3637	pathobionts	abstract[186]|place[187]	new[186]|new[187]	_	_
19-65	3638-3640	in	abstract[186]|place[187]	new[186]|new[187]	_	_
19-66	3641-3644	the	abstract[186]|place[187]|abstract[188]	new[186]|new[187]|giv[188]	_	_
19-67	3645-3652	process	abstract[186]|place[187]|abstract[188]	new[186]|new[187]|giv[188]	_	_
19-68	3653-3655	of	abstract[186]|place[187]|abstract[188]	new[186]|new[187]|giv[188]	_	_
19-69	3656-3666	intestinal	abstract[186]|place[187]|abstract[188]|abstract[190]	new[186]|new[187]|giv[188]|giv[190]	ana	19-77[0_190]
19-70	3667-3674	barrier	abstract[186]|place[187]|abstract[188]|object|abstract[190]	new[186]|new[187]|giv[188]|giv|giv[190]	coref	19-106[203_0]
19-71	3675-3686	alterations	abstract[186]|place[187]|abstract[188]|abstract[190]	new[186]|new[187]|giv[188]|giv[190]	_	_
19-72	3687-3688	,	_	_	_	_
19-73	3689-3694	which	_	_	_	_
19-74	3695-3699	were	_	_	_	_
19-75	3700-3708	followed	_	_	_	_
19-76	3709-3711	by	_	_	_	_
19-77	3712-3717	their	abstract|abstract[192]	giv|new[192]	_	_
19-78	3718-3731	translocation	abstract[192]	new[192]	_	_
19-79	3732-3734	to	abstract[192]	new[192]	_	_
19-80	3735-3740	lymph	abstract[192]|person|place[194]	new[192]|new|new[194]	_	_
19-81	3741-3746	nodes	abstract[192]|place[194]	new[192]|new[194]	_	_
19-82	3747-3750	and	abstract[192]	new[192]	_	_
19-83	3751-3754	the	abstract[192]|place[196]	new[192]|giv[196]	_	_
19-84	3755-3762	hepatic	abstract[192]|place[196]	new[192]|giv[196]	_	_
19-85	3763-3769	portal	abstract[192]|object|place[196]	new[192]|new|giv[196]	_	_
19-86	3770-3776	system	abstract[192]|place[196]	new[192]|giv[196]	_	_
19-87	3777-3778	,	_	_	_	_
19-88	3779-3789	triggering	_	_	_	_
19-89	3790-3798	systemic	abstract[198]	new[198]	appos	19-93[0_198]
19-90	3799-3804	lupus	animal|abstract[198]	new|new[198]	_	_
19-91	3805-3818	erythematosus	abstract[198]	new[198]	_	_
19-92	3819-3820	(	_	_	_	_
19-93	3821-3824	SLE	abstract	giv	_	_
19-94	3825-3826	)	_	_	_	_
19-95	3827-3828	.	_	_	_	_
19-96	3829-3835	Thaiss	person	new	_	_
19-97	3836-3838	et	_	_	_	_
19-98	3839-3842	al.	_	_	_	_
19-99	3843-3851	reported	_	_	_	_
19-100	3852-3856	that	_	_	_	_
19-101	3857-3870	hyperglycemia	event	new	_	_
19-102	3871-3876	leads	_	_	_	_
19-103	3877-3879	to	_	_	_	_
19-104	3880-3890	disruption	event[202]	new[202]	_	_
19-105	3891-3893	of	event[202]	new[202]	_	_
19-106	3894-3897	the	event[202]|object[203]	new[202]|giv[203]	coref	19-126[207_203]
19-107	3898-3908	intestinal	event[202]|object[203]	new[202]|giv[203]	_	_
19-108	3909-3916	barrier	event[202]|object[203]	new[202]|giv[203]	_	_
19-109	3917-3925	followed	_	_	_	_
19-110	3926-3928	by	_	_	_	_
19-111	3929-3939	intestinal	abstract[204]	giv[204]	_	_
19-112	3940-3952	inflammation	abstract[204]	giv[204]	_	_
19-113	3953-3956	and	_	_	_	_
19-114	3957-3965	systemic	event[205]	new[205]	_	_
19-115	3966-3975	infection	event[205]	new[205]	_	_
19-116	3976-3977	.	_	_	_	_
19-117	3978-3985	Spadoni	_	_	_	_
19-118	3986-3988	et	_	_	_	_
19-119	3989-3992	al.	_	_	_	_
19-120	3993-4001	recently	_	_	_	_
19-121	4002-4012	documented	_	_	_	_
19-122	4013-4017	that	_	_	_	_
19-123	4018-4021	the	abstract[206]	new[206]	_	_
19-124	4022-4030	presence	abstract[206]	new[206]	_	_
19-125	4031-4033	of	abstract[206]	new[206]	_	_
19-126	4034-4037	the	abstract[206]|object[207]	new[206]|giv[207]	_	_
19-127	4038-4050	gut-vascular	abstract[206]|object[207]	new[206]|giv[207]	_	_
19-128	4051-4058	barrier	abstract[206]|object[207]	new[206]|giv[207]	_	_
19-129	4059-4060	(	_	_	_	_
19-130	4061-4064	GVB	place	new	coref	21-1[226_0]
19-131	4065-4066	)	_	_	_	_
19-132	4067-4069	in	_	_	_	_
19-133	4070-4073	the	object[209]	giv[209]	coref	22-13[242_209]
19-134	4074-4079	small	object[209]	giv[209]	_	_
19-135	4080-4089	intestine	object[209]	giv[209]	_	_
19-136	4090-4098	controls	_	_	_	_
19-137	4099-4102	the	abstract[210]	new[210]	_	_
19-138	4103-4116	dissemination	abstract[210]	new[210]	_	_
19-139	4117-4119	of	abstract[210]	new[210]	_	_
19-140	4120-4128	bacteria	abstract[210]|animal[211]	new[210]|new[211]	_	_
19-141	4129-4133	into	abstract[210]|animal[211]	new[210]|new[211]	_	_
19-142	4134-4137	the	abstract[210]|animal[211]|place[212]	new[210]|new[211]|new[212]	_	_
19-143	4138-4149	bloodstream	abstract[210]|animal[211]|place[212]	new[210]|new[211]|new[212]	_	_
19-144	4150-4151	.	_	_	_	_

#Text=The authors reported a decrease of the wnt/beta catenin-inducible gene Axin2 ( a marker of stem cell renewal ) in gut endothelium under the presence of Salmonella typhimirum in the SB .
20-1	4152-4155	The	person[213]	new[213]	_	_
20-2	4156-4163	authors	person[213]	new[213]	_	_
20-3	4164-4172	reported	_	_	_	_
20-4	4173-4174	a	event[214]	new[214]	_	_
20-5	4175-4183	decrease	event[214]	new[214]	_	_
20-6	4184-4186	of	event[214]	new[214]	_	_
20-7	4187-4190	the	event[214]|abstract[216]	new[214]|new[216]	appos	20-13[217_216]
20-8	4191-4199	wnt/beta	event[214]|abstract[216]	new[214]|new[216]	_	_
20-9	4200-4217	catenin-inducible	event[214]|abstract[216]	new[214]|new[216]	_	_
20-10	4218-4222	gene	event[214]|abstract|abstract[216]	new[214]|giv|new[216]	_	_
20-11	4223-4228	Axin2	event[214]|abstract[216]	new[214]|new[216]	_	_
20-12	4229-4230	(	event[214]	new[214]	_	_
20-13	4231-4232	a	event[214]|abstract[217]	new[214]|giv[217]	coref	22-26[248_217]
20-14	4233-4239	marker	event[214]|abstract[217]	new[214]|giv[217]	_	_
20-15	4240-4242	of	event[214]|abstract[217]	new[214]|giv[217]	_	_
20-16	4243-4247	stem	event[214]|abstract[217]|abstract[219]	new[214]|giv[217]|new[219]	_	_
20-17	4248-4252	cell	event[214]|abstract[217]|place|abstract[219]	new[214]|giv[217]|new|new[219]	_	_
20-18	4253-4260	renewal	event[214]|abstract[217]|abstract[219]	new[214]|giv[217]|new[219]	_	_
20-19	4261-4262	)	event[214]	new[214]	_	_
20-20	4263-4265	in	event[214]	new[214]	_	_
20-21	4266-4269	gut	event[214]|abstract|place[221]	new[214]|giv|new[221]	_	_
20-22	4270-4281	endothelium	event[214]|place[221]	new[214]|new[221]	_	_
20-23	4282-4287	under	event[214]|place[221]	new[214]|new[221]	_	_
20-24	4288-4291	the	event[214]|place[221]|abstract[222]	new[214]|new[221]|new[222]	_	_
20-25	4292-4300	presence	event[214]|place[221]|abstract[222]	new[214]|new[221]|new[222]	_	_
20-26	4301-4303	of	event[214]|place[221]|abstract[222]	new[214]|new[221]|new[222]	_	_
20-27	4304-4314	Salmonella	event[214]|place[221]|abstract[222]|animal|abstract[224]	new[214]|new[221]|new[222]|new|new[224]	_	_
20-28	4315-4325	typhimirum	event[214]|place[221]|abstract[222]|abstract[224]	new[214]|new[221]|new[222]|new[224]	_	_
20-29	4326-4328	in	event[214]|place[221]|abstract[222]|abstract[224]	new[214]|new[221]|new[222]|new[224]	_	_
20-30	4329-4332	the	event[214]|place[221]|abstract[222]|abstract[224]|abstract[225]	new[214]|new[221]|new[222]|new[224]|giv[225]	coref	23-4[0_225]
20-31	4333-4335	SB	event[214]|place[221]|abstract[222]|abstract[224]|abstract[225]	new[214]|new[221]|new[222]|new[224]|giv[225]	_	_
20-32	4336-4337	.	_	_	_	_

#Text=The GVB was modified in patients with coeliac disease ( CD ) with altered serum transaminases , which suggests that GVB deterioration may be responsible for liver damage in CD patients .
21-1	4338-4341	The	place[226]	giv[226]	coref	21-21[0_226]
21-2	4342-4345	GVB	place[226]	giv[226]	_	_
21-3	4346-4349	was	_	_	_	_
21-4	4350-4358	modified	_	_	_	_
21-5	4359-4361	in	_	_	_	_
21-6	4362-4370	patients	person[227]	giv[227]	coref	21-30[238_227]
21-7	4371-4375	with	person[227]	giv[227]	_	_
21-8	4376-4383	coeliac	person[227]|person|abstract[229]	giv[227]|new|giv[229]	appos|appos	21-11[0_229]|21-11[0_229]
21-9	4384-4391	disease	person[227]|abstract[229]	giv[227]|giv[229]	_	_
21-10	4392-4393	(	_	_	_	_
21-11	4394-4396	CD	abstract	giv	coref	21-30
21-12	4397-4398	)	_	_	_	_
21-13	4399-4403	with	_	_	_	_
21-14	4404-4411	altered	abstract[232]	new[232]	_	_
21-15	4412-4417	serum	abstract|abstract[232]	new|new[232]	_	_
21-16	4418-4431	transaminases	abstract[232]	new[232]	_	_
21-17	4432-4433	,	_	_	_	_
21-18	4434-4439	which	_	_	_	_
21-19	4440-4448	suggests	_	_	_	_
21-20	4449-4453	that	_	_	_	_
21-21	4454-4457	GVB	object|abstract[234]	giv|new[234]	coref|coref	22-26|22-26
21-22	4458-4471	deterioration	abstract[234]	new[234]	_	_
21-23	4472-4475	may	_	_	_	_
21-24	4476-4478	be	_	_	_	_
21-25	4479-4490	responsible	_	_	_	_
21-26	4491-4494	for	_	_	_	_
21-27	4495-4500	liver	object|abstract[236]	giv|new[236]	ana|ana	22-1[0_236]|22-1[0_236]
21-28	4501-4507	damage	abstract[236]	new[236]	_	_
21-29	4508-4510	in	abstract[236]	new[236]	_	_
21-30	4511-4513	CD	abstract[236]|abstract|person[238]	new[236]|giv|giv[238]	coref|coref|coref|coref	22-36[251_238]|25-12|22-36[251_238]|25-12
21-31	4514-4522	patients	abstract[236]|person[238]	new[236]|giv[238]	_	_
21-32	4523-4524	.	_	_	_	_

#Text=It has been shown that disruption of epithelial and vascular barriers in the intestine were early events in non-alcoholic steatohepatitis ( NASH ) , and GVB leakage marker could be identified in colonic biopsies in patients with NASH .
22-1	4525-4527	It	abstract	giv	_	_
22-2	4528-4531	has	_	_	_	_
22-3	4532-4536	been	_	_	_	_
22-4	4537-4542	shown	_	_	_	_
22-5	4543-4547	that	_	_	_	_
22-6	4548-4558	disruption	abstract[240]	new[240]	coref	22-16[243_240]
22-7	4559-4561	of	abstract[240]	new[240]	_	_
22-8	4562-4572	epithelial	abstract[240]|object[241]	new[240]|giv[241]	coref	23-4[255_241]
22-9	4573-4576	and	abstract[240]|object[241]	new[240]|giv[241]	_	_
22-10	4577-4585	vascular	abstract[240]|object[241]	new[240]|giv[241]	_	_
22-11	4586-4594	barriers	abstract[240]|object[241]	new[240]|giv[241]	_	_
22-12	4595-4597	in	abstract[240]|object[241]	new[240]|giv[241]	_	_
22-13	4598-4601	the	abstract[240]|object[241]|object[242]	new[240]|giv[241]|giv[242]	_	_
22-14	4602-4611	intestine	abstract[240]|object[241]|object[242]	new[240]|giv[241]|giv[242]	_	_
22-15	4612-4616	were	_	_	_	_
22-16	4617-4622	early	abstract[243]	giv[243]	_	_
22-17	4623-4629	events	abstract[243]	giv[243]	_	_
22-18	4630-4632	in	abstract[243]	giv[243]	_	_
22-19	4633-4646	non-alcoholic	abstract[243]|abstract[244]	giv[243]|new[244]	appos	22-22[0_244]
22-20	4647-4662	steatohepatitis	abstract[243]|abstract[244]	giv[243]|new[244]	_	_
22-21	4663-4664	(	_	_	_	_
22-22	4665-4669	NASH	abstract	giv	coref	22-38
22-23	4670-4671	)	_	_	_	_
22-24	4672-4673	,	_	_	_	_
22-25	4674-4677	and	_	_	_	_
22-26	4678-4681	GVB	place|abstract[248]	giv|giv[248]	_	_
22-27	4682-4689	leakage	place|abstract[248]	new|giv[248]	_	_
22-28	4690-4696	marker	abstract[248]	giv[248]	_	_
22-29	4697-4702	could	_	_	_	_
22-30	4703-4705	be	_	_	_	_
22-31	4706-4716	identified	_	_	_	_
22-32	4717-4719	in	_	_	_	_
22-33	4720-4727	colonic	abstract|object[250]	new|new[250]	_	_
22-34	4728-4736	biopsies	object[250]	new[250]	_	_
22-35	4737-4739	in	object[250]	new[250]	_	_
22-36	4740-4748	patients	object[250]|person[251]	new[250]|giv[251]	_	_
22-37	4749-4753	with	object[250]|person[251]	new[250]|giv[251]	_	_
22-38	4754-4758	NASH	object[250]|person[251]|abstract	new[250]|giv[251]|giv	coref	25-19
22-39	4759-4760	.	_	_	_	_

#Text=Of importance , SB epithelial and vascular barriers are FXR-controlled , which opens avenues to clinical trials aimed at investigation of novel FXR-agonists as future therapeutics .
23-1	4761-4763	Of	_	_	_	_
23-2	4764-4774	importance	abstract	new	_	_
23-3	4775-4776	,	_	_	_	_
23-4	4777-4779	SB	object|object[255]	giv|giv[255]	coref|coref|coref|coref	23-10[0_255]|25-3[267_0]|23-10[0_255]|25-3[267_0]
23-5	4780-4790	epithelial	object[255]	giv[255]	_	_
23-6	4791-4794	and	object[255]	giv[255]	_	_
23-7	4795-4803	vascular	object[255]	giv[255]	_	_
23-8	4804-4812	barriers	object[255]	giv[255]	_	_
23-9	4813-4816	are	_	_	_	_
23-10	4817-4831	FXR-controlled	object	giv	coref	24-4[261_0]
23-11	4832-4833	,	_	_	_	_
23-12	4834-4839	which	_	_	_	_
23-13	4840-4845	opens	_	_	_	_
23-14	4846-4853	avenues	place	new	_	_
23-15	4854-4856	to	_	_	_	_
23-16	4857-4865	clinical	event[258]	new[258]	_	_
23-17	4866-4872	trials	event[258]	new[258]	_	_
23-18	4873-4878	aimed	_	_	_	_
23-19	4879-4881	at	_	_	_	_
23-20	4882-4895	investigation	abstract[259]	new[259]	_	_
23-21	4896-4898	of	abstract[259]	new[259]	_	_
23-22	4899-4904	novel	abstract[259]|abstract[260]	new[259]|new[260]	_	_
23-23	4905-4917	FXR-agonists	abstract[259]|abstract[260]	new[259]|new[260]	_	_
23-24	4918-4920	as	abstract[259]	new[259]	_	_
23-25	4921-4927	future	abstract[259]	new[259]	_	_
23-26	4928-4940	therapeutics	abstract[259]	new[259]	_	_
23-27	4941-4942	.	_	_	_	_

#Text=Of interest , intestinal barriers could be monitored in vivo with the aid of confocal laser endomicroscopy ( CLE ) .
24-1	4943-4945	Of	_	_	_	_
24-2	4946-4954	interest	_	_	_	_
24-3	4955-4956	,	_	_	_	_
24-4	4957-4967	intestinal	object[261]	giv[261]	coref	27-12[0_261]
24-5	4968-4976	barriers	object[261]	giv[261]	_	_
24-6	4977-4982	could	_	_	_	_
24-7	4983-4985	be	_	_	_	_
24-8	4986-4995	monitored	_	_	_	_
24-9	4996-4998	in	_	_	_	_
24-10	4999-5003	vivo	_	_	_	_
24-11	5004-5008	with	_	_	_	_
24-12	5009-5012	the	abstract[262]	new[262]	_	_
24-13	5013-5016	aid	abstract[262]	new[262]	_	_
24-14	5017-5019	of	abstract[262]	new[262]	_	_
24-15	5020-5028	confocal	abstract[262]|person|object[265]	new[262]|new|new[265]	appos|appos	24-19[0_265]|24-19[0_265]
24-16	5029-5034	laser	abstract[262]|person|object[265]	new[262]|new|new[265]	_	_
24-17	5035-5049	endomicroscopy	abstract[262]|object[265]	new[262]|new[265]	_	_
24-18	5050-5051	(	_	_	_	_
24-19	5052-5055	CLE	object	giv	_	_
24-20	5056-5057	)	_	_	_	_
24-21	5058-5059	.	_	_	_	_

#Text=Therefore , the SB is considered a key player in metabolic disease development , including diabetes mellitus and NASH , and other diet-related disorders such as coeliac and non-coeliac enteropathies .
25-1	5060-5069	Therefore	_	_	_	_
25-2	5070-5071	,	_	_	_	_
25-3	5072-5075	the	substance[267]	giv[267]	coref	26-12[0_267]
25-4	5076-5078	SB	substance[267]	giv[267]	_	_
25-5	5079-5081	is	_	_	_	_
25-6	5082-5092	considered	_	_	_	_
25-7	5093-5094	a	abstract[268]	new[268]	_	_
25-8	5095-5098	key	abstract[268]	new[268]	_	_
25-9	5099-5105	player	abstract[268]	new[268]	_	_
25-10	5106-5108	in	abstract[268]	new[268]	_	_
25-11	5109-5118	metabolic	abstract[268]|person|abstract[271]	new[268]|giv|new[271]	_	_
25-12	5119-5126	disease	abstract[268]|abstract|abstract[271]	new[268]|giv|new[271]	coref	27-35
25-13	5127-5138	development	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-14	5139-5140	,	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-15	5141-5150	including	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-16	5151-5159	diabetes	abstract[268]|abstract[271]|abstract|abstract[273]	new[268]|new[271]|giv|giv[273]	_	_
25-17	5160-5168	mellitus	abstract[268]|abstract[271]|abstract[273]	new[268]|new[271]|giv[273]	_	_
25-18	5169-5172	and	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-19	5173-5177	NASH	abstract[268]|abstract[271]|abstract	new[268]|new[271]|giv	_	_
25-20	5178-5179	,	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-21	5180-5183	and	abstract[268]|abstract[271]	new[268]|new[271]	_	_
25-22	5184-5189	other	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-23	5190-5202	diet-related	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-24	5203-5212	disorders	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-25	5213-5217	such	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-26	5218-5220	as	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-27	5221-5228	coeliac	abstract[268]|abstract[271]|abstract[275]|abstract	new[268]|new[271]|new[275]|new	_	_
25-28	5229-5232	and	abstract[268]|abstract[271]|abstract[275]	new[268]|new[271]|new[275]	_	_
25-29	5233-5244	non-coeliac	abstract[268]|abstract[271]|abstract[275]|object[277]	new[268]|new[271]|new[275]|new[277]	_	_
25-30	5245-5258	enteropathies	abstract[268]|abstract[271]|abstract[275]|object[277]	new[268]|new[271]|new[275]|new[277]	_	_
25-31	5259-5260	.	_	_	_	_

#Text=Another major field is drug metabolism and its interaction with small bowel microbiome .
26-1	5261-5268	Another	abstract[278]	new[278]	coref	26-5[279_278]
26-2	5269-5274	major	abstract[278]	new[278]	_	_
26-3	5275-5280	field	abstract[278]	new[278]	_	_
26-4	5281-5283	is	_	_	_	_
26-5	5284-5288	drug	abstract[279]	giv[279]	_	_
26-6	5289-5299	metabolism	abstract[279]	giv[279]	_	_
26-7	5300-5303	and	abstract[279]	giv[279]	_	_
26-8	5304-5307	its	abstract[279]|abstract[280]	giv[279]|new[280]	_	_
26-9	5308-5319	interaction	abstract[279]|abstract[280]	giv[279]|new[280]	_	_
26-10	5320-5324	with	abstract[279]|abstract[280]	giv[279]|new[280]	_	_
26-11	5325-5330	small	abstract[279]|abstract[280]|object[282]	giv[279]|new[280]|new[282]	_	_
26-12	5331-5336	bowel	abstract[279]|abstract[280]|object|object[282]	giv[279]|new[280]|giv|new[282]	coref	27-19[288_0]
26-13	5337-5347	microbiome	abstract[279]|abstract[280]|object[282]	giv[279]|new[280]|new[282]	_	_
26-14	5348-5349	.	_	_	_	_

#Text=Moreover , the emergence of gut-brain , gut-liver , and gut-blood barriers point towards the important role of the SB in the pathogenesis of previously unthought and GI-unrelated conditions such as neurodegenerative and cardiovascular disease .
27-1	5350-5358	Moreover	_	_	_	_
27-2	5359-5360	,	_	_	_	_
27-3	5361-5364	the	abstract[283]	new[283]	_	_
27-4	5365-5374	emergence	abstract[283]	new[283]	_	_
27-5	5375-5377	of	abstract[283]	new[283]	_	_
27-6	5378-5387	gut-brain	abstract[283]|place	new[283]|new	_	_
27-7	5388-5389	,	abstract[283]	new[283]	_	_
27-8	5390-5399	gut-liver	abstract[283]|place	new[283]|new	_	_
27-9	5400-5401	,	_	_	_	_
27-10	5402-5405	and	_	_	_	_
27-11	5406-5415	gut-blood	_	_	_	_
27-12	5416-5424	barriers	object	giv	_	_
27-13	5425-5430	point	_	_	_	_
27-14	5431-5438	towards	_	_	_	_
27-15	5439-5442	the	abstract[287]	new[287]	_	_
27-16	5443-5452	important	abstract[287]	new[287]	_	_
27-17	5453-5457	role	abstract[287]	new[287]	_	_
27-18	5458-5460	of	abstract[287]	new[287]	_	_
27-19	5461-5464	the	abstract[287]|object[288]	new[287]|giv[288]	coref	28-1[293_288]
27-20	5465-5467	SB	abstract[287]|object[288]	new[287]|giv[288]	_	_
27-21	5468-5470	in	abstract[287]	new[287]	_	_
27-22	5471-5474	the	abstract[287]|abstract[289]	new[287]|new[289]	_	_
27-23	5475-5487	pathogenesis	abstract[287]|abstract[289]	new[287]|new[289]	_	_
27-24	5488-5490	of	abstract[287]|abstract[289]	new[287]|new[289]	_	_
27-25	5491-5501	previously	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-26	5502-5511	unthought	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-27	5512-5515	and	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-28	5516-5528	GI-unrelated	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-29	5529-5539	conditions	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-30	5540-5544	such	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-31	5545-5547	as	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-32	5548-5565	neurodegenerative	abstract[287]|abstract[289]|abstract[290]|abstract	new[287]|new[289]|new[290]|new	_	_
27-33	5566-5569	and	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-34	5570-5584	cardiovascular	abstract[287]|abstract[289]|abstract[290]	new[287]|new[289]|new[290]	_	_
27-35	5585-5592	disease	abstract[287]|abstract[289]|abstract[290]|abstract	new[287]|new[289]|new[290]|giv	_	_
27-36	5593-5594	.	_	_	_	_

#Text=The SB remains an organ that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge .
28-1	5595-5598	The	object[293]	giv[293]	coref	30-14[302_293]
28-2	5599-5601	SB	object[293]	giv[293]	_	_
28-3	5602-5609	remains	_	_	_	_
28-4	5610-5612	an	object[294]	new[294]	_	_
28-5	5613-5618	organ	object[294]	new[294]	_	_
28-6	5619-5623	that	_	_	_	_
28-7	5624-5626	is	_	_	_	_
28-8	5627-5636	difficult	_	_	_	_
28-9	5637-5639	to	_	_	_	_
28-10	5640-5645	fully	_	_	_	_
28-11	5646-5652	access	_	_	_	_
28-12	5653-5656	and	_	_	_	_
28-13	5657-5663	assess	_	_	_	_
28-14	5664-5667	and	_	_	_	_
28-15	5668-5676	accurate	event[295]	new[295]	_	_
28-16	5677-5686	diagnosis	event[295]	new[295]	_	_
28-17	5687-5692	often	_	_	_	_
28-18	5693-5698	poses	_	_	_	_
28-19	5699-5700	a	abstract[296]	new[296]	_	_
28-20	5701-5709	clinical	abstract[296]	new[296]	_	_
28-21	5710-5719	challenge	abstract[296]	new[296]	_	_
28-22	5720-5721	.	_	_	_	_

#Text=Undoubtedly , the therapeutic potential remains untapped .
29-1	5722-5733	Undoubtedly	_	_	_	_
29-2	5734-5735	,	_	_	_	_
29-3	5736-5739	the	abstract[297]	new[297]	ana	30-3[0_297]
29-4	5740-5751	therapeutic	abstract[297]	new[297]	_	_
29-5	5752-5761	potential	abstract[297]	new[297]	_	_
29-6	5762-5769	remains	_	_	_	_
29-7	5770-5778	untapped	_	_	_	_
29-8	5779-5780	.	_	_	_	_

#Text=Therefore , it is now time to direct more of our interest towards the SB and unravel the interplay between the SB and other GI and non-GI related diseases .
30-1	5781-5790	Therefore	_	_	_	_
30-2	5791-5792	,	_	_	_	_
30-3	5793-5795	it	abstract	giv	coref	30-5[299_0]
30-4	5796-5798	is	_	_	_	_
30-5	5799-5802	now	abstract[299]	giv[299]	_	_
30-6	5803-5807	time	abstract[299]	giv[299]	_	_
30-7	5808-5810	to	_	_	_	_
30-8	5811-5817	direct	_	_	_	_
30-9	5818-5822	more	_	_	_	_
30-10	5823-5825	of	_	_	_	_
30-11	5826-5829	our	person|abstract[301]	giv|new[301]	_	_
30-12	5830-5838	interest	abstract[301]	new[301]	_	_
30-13	5839-5846	towards	_	_	_	_
30-14	5847-5850	the	abstract[302]	giv[302]	coref	30-21[304_302]
30-15	5851-5853	SB	abstract[302]	giv[302]	_	_
30-16	5854-5857	and	_	_	_	_
30-17	5858-5865	unravel	_	_	_	_
30-18	5866-5869	the	abstract[303]	new[303]	_	_
30-19	5870-5879	interplay	abstract[303]	new[303]	_	_
30-20	5880-5887	between	abstract[303]	new[303]	_	_
30-21	5888-5891	the	abstract[303]|abstract[304]	new[303]|giv[304]	_	_
30-22	5892-5894	SB	abstract[303]|abstract[304]	new[303]|giv[304]	_	_
30-23	5895-5898	and	abstract[303]	new[303]	_	_
30-24	5899-5904	other	abstract[303]|organization[305]	new[303]|giv[305]	_	_
30-25	5905-5907	GI	abstract[303]|organization[305]	new[303]|giv[305]	_	_
30-26	5908-5911	and	abstract[303]	new[303]	_	_
30-27	5912-5918	non-GI	abstract[303]|abstract[306]	new[303]|giv[306]	_	_
30-28	5919-5926	related	abstract[303]|abstract[306]	new[303]|giv[306]	_	_
30-29	5927-5935	diseases	abstract[303]|abstract[306]	new[303]|giv[306]	_	_
30-30	5936-5937	.	_	_	_	_
